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A B S T R A C T
The objectives of the work were to develop a lipid based delivery system for aspirin and to
evaluate its physicochemical and pharmacodynamic properties. Aspirin-loaded solid lipid
microparticles (SLMs) were formulated by hot homogenization and analysed for their en-
capsulation efficiency (EE%), in vitro release, particle size, anti-inflammatory and ulcer inhibition
properties. Particle size ranged from 33.10 ± 5.85 to 43.50 ± 7.27 µm for batches A1 to A3 SLMs
loaded with 1, 3 and 5% aspirin and containing Poloxamer 407, while batches B1, B2 and
B3 formulated with Soluplus as surfactant had particle size range of 31.10 ± 1.46 to
45.60 ± 2.92 µm. Batches A1 and B1 containing 1% of aspirin had the highest EE of 70 and
72% respectively. Maximum in vitro release of 95.1 and 93.2% were obtained at 8 h from batches
A1 and B1 respectively. SLMs exhibited about 77.8% oedema inhibition, while the refer-
ence had 66.7% and ulcer inhibition range of 25–75%. Aspirin-loaded SLMs exhibited good
properties and could be used orally twice daily for the treatment of inflammation.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Shenyang Phar-
maceutical University. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Aspirin is one of the oldest drugs used in the treatment of pain
and inflammation; however, recently this drug has been pre-
scribed for a host of indications. In addition to its use as an
analgesic, anti-inflammatory, and antipyretic agent, it is indi-
cated for use in the prevention and treatment of heart disease
and stroke [1]. Further studies are under way investigating the
potentials of aspirin in boosting the immune system, treat-
ing cognitive decline, and lowering the risk of colon and ovarian
cancer [1]. Despite these attributes, it suffers a lot of side effects
with the gastrointestinal (GI) side effect being the most promi-
nent in patients on daily dose of aspirin. Aspirin has been
regarded as a potential gastric irritant and studies have shown
that the incidence of gastrointestinal side effects may in-
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crease with regular use [1]. Because of this, aspirin is preferably
formulated in the form of enteric coated formulations.
Aspirin is a moisture-sensitive drug and can hydrolyse into
acetic and salicylic acids when exposed to high humidity and
elevated temperatures, coating could subject aspirin tablets
to both high temperatures and humidity [1]. Mitrevej and
Hollenbeck found that a hydrophilic field generated around
aspirin crystals under high-humidity conditions and upon com-
bining the drug with certain tablet excipients like hydrophilic
disintegrants may lead to condensation of aspirin crystals [2].
Because of all these problems encountered in formulating
aspirin tablets, the GI side effects and because of the impor-
tance of this drug in the treatment of ailments, a new delivery
system that will prevent the GI side effects as well as reduce
the rigors involved in formulation is very important so as to
enhance patient acceptability of this drug, reduce or elimi-
nate gastric irritation and enhance the efficacy of this
drug [1].
Solid lipid microparticles (SLM) are micro-scale drug car-
riers possessing a matrix made from fatty acid, glyceride,
fatty alcohol, and solid wax with high melting points [3]. They
combine many advantages of drug carrier systems. The
amount of drug encapsulated can vary up to 95% for lipo-
philic and hydrophilic drugs and because they are made
from physiological or physiologically related materials, they
are well tolerated in living systems. The solid matrix
protects loaded labile substances against degradation and it
offers the possibility of controlled drug release and drug tar-
geting [4–6]. Compared to the polymer microparticles, SLMs
have the advantage of better biocompatibility, which mini-
mizes the hazards of acute and chronic toxicity; they possess
solid cores which reduce the mobility of incorporated drug
and drug leakage from the carriers. They can be produced on
a large industrial scale and are easy to produce [7,8]. They
also have the ability to mask the taste of some drugs and
have been shown to enhance the absorption of both hydro-
philic and lipophilic drugs and have been shown to protect
the GI against the gastric irritation side effects of non steroi-
dal anti-inflammatory drugs (NSAIDs) [5–9]. Because of all these
quality attributes of SLMs, we decided to investigate its prop-
erties on aspirin. Therefore, the aims of the work were to
formulate aspirin-loaded SLMs in order to investigate its
ability to protect the drug from hydrolysis, and also to study
the anti-inflammatory and anti ulcer properties of the
formulations.
2. Materials and methods
2.1. Materials
The following materials were used as supplied by the local sup-
pliers with no further modifications: Phospholipon® 90H
(Phospholipid GmbH, Köln, Germany), sorbic acid (Sigma®
Chemical Company, USA), sorbitol (Qualikems Laboratory
Reagent, India), Poloxamer® 407 (Synochem City, Germany),
Soluplus®, sodium hydroxide, monobasic sodium phosphate
(Merck, Darmstadt, Germany), goat fat (Quarter market, Awka,
Nigeria), activated charcoal (Bio–Lab, UK), aspirin (Evans Phar-
maceutical Ltd., England), and distilled water (Lion Water,
Nsukka, Nigeria).
2.2. Extraction of goat fat
The fat was extracted by grating the adipose tissue prior to
boiling with half its weight of water on a water bath for 45 min.
Molten fat was separated from the aqueous phase using a
muslin cloth. Further purification was carried out by heating
a 2% w/w suspension of a 1:9 ratio blend with activated char-
coal and bentonite at 80–90 °C for 1 h.Thereafter, the suspension
was vacuum-filtered using Buchner funnel [10].
2.3. Preparation of lipid matrix (LM)
The lipid matrix was prepared by fusion using Phospholipon®
90H (30 g) and purified goat fat (70 g). The lipids were weighed
and melted together in a beaker placed on a magnetic stirrer
hot plate (SR1 UM 52188, Remi Equip., India) at 70 °C and stirred
with a glass stirrer until a transparent homogenous white melt
was obtained. The lipid matrix was stirred continuously until
it solidified at room temperature [6].
2.4. Formulation of the SLMs
The aspirin-loaded SLMs were prepared using the melt ho-
mogenization technique according to the formula presented
in Table 1. In each case, 5 g of the lipid matrix was melted at
80 °C on a water bath and an appropriate amount of aspirin
was incorporated into the lipidic melt. Sorbitol, Soluplus or
poloxamer as the case may be were dissolved in hot distilled
water at the same temperature with the lipidic melt. The hot
Table 1 – Formula for different batches of SLMs.
Batch LM
(%)
Aspirin
(%)
Soluplus®
(%)
Poloxamer
407 (%)
Sorbitol
(%)
Sorbic
acid (%)
Distilled
water (%)
A1 5 1 – 4 4 0.05 100
A2 5 3 – 4 4 0.05 100
A3 5 5 – 4 4 0.05 100
A4 5 – – 4 4 0.05 100
B1 5 1 2 – 4 0.05 100
B2 5 3 2 – 4 0.05 100
B3 5 5 2 – 4 0.05 100
B4 5 – 2 – 4 0.05 100
A1, A2, A3 and A4 were formulated with Poloxamer 407 and contain 1, 3, 5 and 0% aspirin respectively, while, B1, B2, B3 and B4 were formu-
lated with Soluplus and contain 1, 3, 5 and 0% aspirin respectively.
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aqueous phase was transferred into the molten lipid and im-
mediately homogenized with Ultra-Turrax (T25 Basic, Digital,
Ika Staufen, Germany) at 7200 rpm for 10 min. SLMs contain-
ing no drug (unloaded lipospheres) were also formulated [10,11].
2.5. Lyophilization of liquid SLMs
A 50 ml quantity of the SLMs was lyophilized using a freeze-
dryer (Amsco/Finn-Aqua Lyovac GT3, Germany), the sample
formulation was added into 250 ml conical flask, the flask was
attached to the vacuum pressure pump and the formula-
tions were lyophilized in order to obtain water free SLMs.
2.6. Determination of percentage yield
The percentage yield was determined after lyophilization using
the equation:
Percentage yield =
+
×
W
W W
1
2 3
100 (1)
where W1 is weight of SLM (g), W2 is weight of drug loaded (g)
and W3 is weight of excipients (g) [12].
2.7. Differential scanning calorimetric analysis
A 1 mg quantity of the individual lipids, the lipid matrices and
the SLMs were weighed into an aluminium pan, hermetically
sealed and the thermal behaviour determined using a calo-
rimeter (Netzsch DSC 204 F1, Germany), in the range of 10–
400 °C at a heating rate of 5 °C/min. Baselines were determined
using an empty pan, and all the thermograms were baseline
corrected.
2.8. Particle size and morphology determination
The particle size of the SLMs was determined by computer-
ized image analysis of at least 100 microparticles. The
lyophilized SLMs were dispersed in little amount of distilled
water on a microscope slide, covered with a cover slip and
imaged under a binocular microscope (Leica, Germany) at-
tached with a Motic image analyser (Moticam, China) at a
magnification of ×400. The particle morphologies were also ob-
served and photomicrographs were taken.
2.9. Time-dependent pH stability studies
About 5% of the lyophilized lipospheres were prepared in dis-
tilled water and the pH of dispersions of drug loaded and
unloaded lipospheres were determined in a time dependent
manner: 1 day, 30 days and 90 days using a pH meter (pH ep®
Hanna Instruments, Padova, Italy).
2.10. Drug content and encapsulation efficiency analysis
Beer–Lambert’s plot of aspirin was obtained at a concentra-
tion range of 0.1–0.8 mg% using water as the medium and at
a predetermined wavelength of 300 nm. The drug content was
determined in the unlyophilized SLMs immediately after prepa-
ration and also in the lyophilized formulations. A 5 ml quantity
of unlyophilized SLMs from each of the batches were centri-
fuged at 1252 × g for 30 min (Chem. Lab. Instrument, UK). The
supernatant was diluted with water, filtered using a filter paper
(Whatman no. 1) and analysed in spectrophotometer (UNICO
2102 PC UV/Vis Spectrophotometer, USA). The actual drug
content (ADC) was determined by subtracting the actual mass
of aspirin in the supernatant from the total amount of aspirin
incorporated in the formulation (or the theoretical drug content).
The experiment was repeated using the 0.5 g of lyophi-
lized formulation; the SLMs were extracted by triturating with
distilled water, filtered and analysed as above for drug content.
The experiment was repeated for each formulation and en-
capsulation efficiency (EE %) was calculated from the equation
below:
EE
TDC
%( ) = ×ADC 100 (2)
where, ADC is the actual drug content and TDC is the theo-
retical drug content.
2.11. In vitro release studies
Beer’s plot was obtained for aspirin in simulated intestinal fluid
(SIF) (pH 7.2) at a concentration range of 0.1 to 0.8 mg/ml at a
predetermined wavelength of 300 nm. The USP paddle method
was adopted in this study. About 900 ml of SIF (pH 7.2) main-
tained at a temperature of 37 ± 1 °C was used for the study. The
dialysis membrane containing the formulation was placed
inside a tightly secured basket and the basket was placed in
the bottom of the beaker. The paddle was rotated at 100 rpm.
About 5 ml was withdrawn from the dissolution medium at
0.5, 1.0, 1.5, 2.0, 3, 5 and 8 h, filtered with a non adsorbent filter
paper (Whatman No. 1) and analysed using a spectrophotom-
eter (UNICO 2102 PC UV/Vis Spectrophotometer, USA) at 300 nm.
An equal volume of the withdrawn sample was replaced with
a fresh medium to maintain sink condition in each case. The
amount of drug released at each time interval was deter-
mined with reference to the standard Beer’s plot. The
experiment was repeated two times for each sample and the
mean was calculated.
2.12. In vitro release kinetics
The dissolution data obtained were analysed to determine the
in vitro release kinetic mechanism using four kinetic models
including the first order, Higuchi square root equation and
Ritger–Peppas empirical model as shown:
Q e k t= −( )−100 1 1 (3)
Q K t= ( )2 1 2 (4)
M M K tt n∝ = 3 (5)
where Q is the percentage drug released at time, t and K1, K2
and K3 are the rate constants of first-order, Higuchi and
Ritger–Peppas models, respectively. Mt/M∝ is fraction of drug
released at time t, n is diffusion exponent and is indicator of
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the mechanism of transport of drug through the formula-
tion, k is kinetic constant (having units of t−n) incorporating
structural and geometric characteristics of the delivery system
[13–16].
2.13. Pharmacodynamic studies
2.13.1. Anti-inflammatory studies
The anti-inflammatory activity of aspirin-loaded SLMs was
carried out using the rat paw oedema test [17]. All animal ex-
perimental protocols were carried out in accordance with
guidelines of the Animal Ethics Committee of the Faculty of
Pharmaceutical Sciences, University of Nigeria, Nsukka. The
phlogistic agent employed in the study was fresh undiluted
egg albumin. Wistar rats of either sex (90–150 g) were divided
into eight experimental groups of five rats per group. The
animals were fasted and deprived of water for 12 h before the
experiment. The deprivation of water was to ensure uniform
hydration and to minimize variability in oedematous re-
sponse [18]. The aspirin-loaded SLMs (Batches A1, A2, A3, B1,
B2 and B3) equivalent to 200 mg/kg body weight was admin-
istered orally to the rats (Groups A–F). The reference group
received 200 mg/kg of pure sample of aspirin (Batch G), while
the control group received normal saline (10 ml/kg) (Batch H).
Thirty minutes post treatment, oedema was induced by in-
jection of 0.1 ml fresh undiluted egg albumin into the sub
plantar region of the right hind paw of the rats. The volumes
of distilled water displaced by treated right hind paw of the
rats were measured using plethysmometer before and at 30 min,
1, 1.5, 2, 2.5, 3, 3.5 and 4 h after egg albumin injection. The anti-
inflammatory activity was calculated at each time as per cent
inhibition of oedema using the relation:
% inhibition
Vo Vt
Vo
=
−
× 100 (6)
where, Vt is the volume of oedema at corresponding time and
Vo is the volume of oedema in control rats at the same time
[11,19–21].
2.13.2. Ulcerogenicity of SLMs
The studies were carried out on healthy Wistar rats (150–
210 g).The animals were divided into eight experimental groups
of five animals per group. The aspirin-loaded SLMs (Batches
A1, A2, A3, B1, B2 and B3) equivalent to 200 mg/kg body weight
was dispersed in water and administered orally to the rats
(Groups A–F) using a syringe. The reference group received
200 mg/kg of pure sample of aspirin (Batch G), the control group
received normal saline (10 ml/kg) (Batch H), while the refer-
ence group received 200 mg/kg pure sample of aspirin orally.
The animals were fasted for 8 h prior to a single dose of either
the control or the test compounds, given free access to food
and water, and sacrificed 17 h later by ether anaesthesia. The
gastric mucosae of the rats were examined under micro-
scope using a 4× binocular magnifier. The lesions were counted
and divided into large (greater than 2 mm in diameter), small
(1–2 mm) and punctiform (less than 1 mm). For each stomach,
the severity of mucosal damage was assessed according to the
following scoring system: 0 – no lesions or one punctiform
lesion; 1 – two to five punctiform lesions; 2 – one to five small
ulcers; 3 – more than five small ulcers or one large ulcer; 4 –
more than one large ulcer [5,22].
2.14. Data and statistical analysis
Statistical analysis was performed using SPSS Version 16.0 (SPSS
Inc., Chicago, IL, USA). All values were expressed as mean ± SD.
Data were analysed by one-way ANOVA, followed by the Duncan
multiple comparison test. Statistical significance was set at
P < 0.05.
3. Results
3.1. Differential scanning calorimetry (DSC)
The results of the DSC thermograms of aspirin, goat fat, lipid
matrices and drug-loaded SLMs (A1 and B1) are shown in Fig. 1
and show that aspirin exhibited sharp endothermic melting
peak at 141.1 °C. The thermograms of goat fat showed endo-
thermic melting peak at 58.7 °C, while the lipid matrix showed
two major endothermic peaks at 59.7 and 77.4 °C.The DSC ther-
mograms of aspirin-loaded SLMs formulated with Poloxamer
407 (A1) and Soluplus (B1) respectively and containing 1% of
aspirin showed endothermic peaks corresponding to the com-
position of the SLM with the endothermic peaks of aspirin at
95.4 and 96.8 °C respectively.
The results of the differential scanning calorimetry of the
goat fat showed melting peak confirming that it was pure; the
DSC thermograms of the lipid matrix (goat fat: P90H) showed
that it had reduced crystallinity, therefore there was distor-
tion of the chemical structures of the individual lipid thereby
creating spaces for drug localization. This was confirmed by
the broad endothermic peaks observed in the lipid matrix (LM).
These results, however, were in agreement with the work done
by Uronnachi et al. [23], who also prepared SLMs of zidovudine
with goat fat and P90H as the lipid matrix. The DSC thermo-
grams of aspirin showed sharp endothermic peak at 141 °C
which confirmed that the drug used was pure and crystalline
and the melting peak was close to that quoted for aspirin in
the official book [24]. When the drug was incorporated into the
SLMs the melting peaks of aspirin were reduced and this
showed that the crystallinity of the drug was reduced espe-
cially in batch A1.
3.2. Particle size and morphology
The results of the particle size of aspirin-loaded and un-
loaded SLMs (lyophilized) are shown in Table 2 and showed that
particle size ranged from 33.10 ± 5.85 to 43.50 ± 7.27 µm for
batches A1 to A3 SLMs loaded with 1, 3 and 5% aspirin and con-
taining Poloxamer 407, while batches B1, B2 and B3 formulated
with Soluplus had particle size range of 31.10 ± 1.46 to
45.60 ± 2.92 µm. The results of the particle morphology of
aspirin-loaded and bland SLMs are shown in Fig. 2 and show
that the SLMs were spherical and smooth. The results showed
that particle size was not directly proportional to drug loading.
However, particle size increased significantly with EE% as shown
in Table 2. Also, SLMs containing 1% of drug exhibited the
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highest particle size than the other formulations (A1 and B1).
However, the bland SLMs containing Soluplus as the surfac-
tant (B4) exhibited particle size greater than some of the drug
loaded SLMs. This may be due to drug entrapment which may
have actuated bending and tilting of the hydrocarbon chains
of the lipid matrix with consequent size reduction. Therefore
without drug entrapment, there is little or no stress im-
pinged on the amphiphilic particle. Hence the observed larger
particle sizes seen in the unloaded SLMs [11]. The particle mor-
phology revealed that the SLMs were spherical. The spherical
shape of particles may be attributed to high shear force of the
homogenizer [11]. Also, the presence of a suitable lyoprotectant
(sorbitol) used in the formulation resulted to the smooth nature
of the SLMs, even after lyophilization. Particle size however,
was not significantly affected by the nature of the surfactant
used (P < 0.05).
3.3. Encapsulation efficiency (EE%)
The results of the EE% of aspirin-loaded SLMs are shown in
Table 2 and show that the SLMs had EE% range of 46.7 to 72.0%
in all the batches. However, batches A1 and B1 containing 1%
of aspirin recorded the highest EE of 70 and 72% respectively.
The results of the EE% showed that generally, the formula-
tions exhibited high EE values; however EE varied directly with
particle size and inversely with drug loading. Increase in drug
loading decreased significantly the EE% of the SLMs. This may
be due to saturation of the lipid matrices with increased drug
content.Therefore, to reduce this problem, the lipid matrix may
be increased above the amount used.
3.4. The pH of the SLMs
The results of the pH of the SLMs are shown in Fig. 3 and show
that the pH of aspirin-loaded SLMs increased from 2.4 to 3.5
for batch A1 SLMs, but this increase was not significant (P < 0.05);
however, the pH remained in the acidic region all through the
study. The pH of the unloaded SLMs also increased from 5.9
to 6.6 at 14 days and later decreased at 30 and 90 days. However,
the aspirin pure sample retained a stable pH throughout the
study. The results of the pH of the aspirin-loaded SLMs showed
an increased pH over time; however, these increases were not
significant (P < 0.05). The unloaded SLMs also had pH in-
crease attesting to the fact that the increase was not due to
drug degradation. Researchers over time have found that in SLM
formulations, pH increases are usually due to the release of
free fatty acids from the individual lipids [6,9,12].
Fig. 1 – DSC thermograms of aspirin, goat fat (GF), lipid matrix (LM), batches A1 (1% aspirin and Poloxamer 407) and B1 (1%
aspirin and Soluplus).
Table 2 – Some physicochemical properties of aspirin-
loaded and unloaded SLMs.
Batches Particle
size (mµ)a
TDC (%) ADC (%)b EE (%)
A1 43.50 ± 7.31 1 0.72 ± 0.45 72.0
A2 33.10 ± 5.85 3 1.40 ± 0.70 46.7
A3 43.50 ± 7.27 5 2.5 ± 0.17 50.0
A4 16.60 ± 2.92 – – –
B1 45.60 ± 2.92 1 0.70 ± 0.12 70.0
B2 31.10 ± 1.46 3 1.42 ± 0.09 47.3
B3 45.50 ± 2.92 5 2.52 ± 0.11 50.4
B4 41.40 ± 3.20 – – –
A1, A2, A3 and A4 were formulated with Poloxamer 407 and contain
1, 3, 5 and 0% aspirin respectively, while, B1, B2, B3 and B4 were for-
mulated with Soluplus and contain 1, 3, 5 and 0% aspirin respectively.
TDC: Theoretical drug content, ADC: Actual drug content, EE: En-
capsulation efficiency.
a n = 100.
b n = 5.
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3.5. In vitro drug release
The results of the in vitro drug release are shown in Fig. 4 and
show that drug release at 0.5 h was up to 60% in most of the
formulations. At 3 h, about 89.1, 72.4 and 80% of aspirin were
released from batches A1, A2 and A3 containing Poloxamer 407
and 1, 3 and 5% of aspirin, while about 88, 72 and 71.2% of drug
were released from aspirin-loaded SLMs formulated with
Soluplus and containing 1, 3 and 5% aspirin (batches B1, B2 and
B3) respectively. The results show that maximum releases of
95.1 and 93.2% were obtained at 8 h from batches A1 and B1
respectively.The results of the in vitro drug release of the aspirin-
loaded SLMs showed that the formulations had very high drug
release within the first 0.5–1 h, an effect like a burst release.
However, this is often encountered in lyophilized SLMs because
of the presence of unencapsulated drug or loosely bound drug
Fig. 2 – Photomicrographs of aspirin-loaded and unloaded SLMs; A1 and A4 were formulated with Poloxamer 407 and
contain 1 and 0% aspirin respectively, while, B1 and B4 were formulated with Soluplus and contain 1 and 0% aspirin
respectively.
Fig. 3 – The pH of unlyophilized SLMs at 30 °C; A1, A2, A3
and A4 were formulated with Poloxamer 407 and contain 1,
3, 5 and 0% aspirin respectively, while, B1, B2, B3 and B4
were formulated with Soluplus and contain 1, 3, 5 and 0%
aspirin respectively.
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Fig. 4 – In vitro drug release profile of aspirin-loaded SLMs;
A1, A2, and A3 were formulated with Poloxamer 407 and
contain 1, 3 and 5% aspirin respectively, while, B1, B2 and
B3 were formulated with Soluplus and contain 1, 3 and 5%
aspirin respectively.
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in the peripheral region of the SLMs. This effect is however,
advantageous in aspirin formulations especially as an anal-
gesic, antipyretic, anti-inflammatory agent and in the
management of various heart conditions. This is because an
initial high concentration is reached i.e. above minimum ef-
fective concentration, before maintaining the dose for a
prolonged period. Therefore, this formulation may be used for
twice daily application.
3.6. In vitro release kinetics
The results of the in vitro release kinetics of the aspirin-
loaded SLMs are shown in Table 3 and show that the first order
plots were linear in all the batches. Also the Ritger–Peppas plots
were linear and the n values were significantly less than 0.5
(P < 0.05).The regression values (r2) obtained from Higuchi plots
also were linear showing that diffusion was implicated as one
of the mechanisms of drug release from the SLM formula-
tions. The results showed that the formulations followed first
order release kinetics. However, the results of the Higuchi plots
revealed that the release mechanism involved diffusion con-
trolled process. Therefore, the release mechanism involved not
only dissolution controlled process but also, diffusion. The
Ritger–Peppas mechanism revealed that the formulations fol-
lowed Fickian diffusion release (n ≤ 0.43, non swellable spheres)
[14–16].
3.7. The anti-inflammatory properties
The results of the anti-inflammatory properties of the aspirin-
loaded SLMs are shown in Table 4 and show that at T1.5 h (i.e.
1.5 h) about 78.3 and 84% of oedema inhibition were ob-
tained in rats that received batches A3 and B1 respectively, while
the reference group (G) had 84% oedema inhibition. Also, at T3 h,
batches A3 and B1 had oedema inhibition of 72.2 and 77.8%,
while the reference had 66.7%.The results showed that the for-
mulations exhibited significant higher anti-inflammatory
properties than aspirin pure sample used as the reference drug
(P < 0.05). The phospholipid component of the SLM was re-
sponsible for improved anti-inflammatory activity. The
phospholipid constituent (lecithin) was believed to facilitate
drug absorption via lymphatic circulation. Lipids from lymph
lipid precursor pool (LLPP) are known to assemble into lipo-
proteins which are transported from the enterocyte via the
lymphatic system into the systemic circulation [11]. This ex-
plains the reason for the higher anti-inflammatory properties
of the SLM formulations.
3.8. Ulcer inhibition properties
The results of ulcer inhibition properties of aspirin-loaded SLMs
are shown in Table 5 and show that the SLMs had per cent ulcer
inhibition range of 25–75% with lesions ranging from 1 to 2 mm
in diameter.The results also revealed that the formulations ex-
hibited significantly higher ulcer inhibition than the reference
drug (P < 0.05). These results however, were in agreement with
the work done by Obitte et al. [11], Chime et al. [5], and Momoh
et al. [9], who individually found out that SLM formulations in-
hibited the ulcer potentials of most NSAIDs.
4. Conclusion
This research has proven that aspirin could be formulated as
SLMs. The need for a new delivery system for this drug cannot
be over emphasized. This is because SLM formulations of this
drug significantly enhanced absorption. Other advantages
Table 3 – In vitro release kinetics.
Batch First order Higuchi Ritger–Peppas
r2 r2 n r2
A1 0.911 0.944 0.183 0.951
A2 0.996 0.993 0.183 0.969
A3 0.958 0.910 0.235 0.912
B1 0.984 0.924 0.171 0.982
B2 0.974 0.938 0.194 0.982
B3 0.961 0.972 0.119 0.948
A1, A2, and A3 were formulated with Poloxamer 407 and contain
1, 3 and 5% aspirin respectively, while, B1, B2 and B3 were formu-
lated with Soluplus and contain 1, 3 and 5% aspirin respectively.
Table 4 – Anti-inflammatory properties of aspirin-loaded SLMs.
Percentage inhibition (%) Normal
saline
(H) (P/V ml)
Time (h) A1 A2 A3 B1 B2 B3 Pure aspirin (G)
0.5 78.33 ± 2.87e 80.55 ± 4.8e 82.22 ± 1.92e 81.33 ± 2.3c 80.00 ± 0.00e 80.50 ± 0.00e 84.40 ± 3.92e 0.08 ± 2.3b
1 80.00 ± 0.00e 80.00 ± 0.0e 81.11 ± 1.92e 84.00 ± 0.0c 79.44 ± 4.19e 81.50 ± 3.77e 80.00 ± 0.00de 0.43 ± 2.3c
1.5 76.67 ± 2.87e 78.33 ± 2.8de 80.00 ± 0.00e 84.00 ± 0.0c 72.22 ± 4.8de 80.50 ± 2.60e 80.00 ± 0.00de 0.43 ± 2.3c
2 75.00 ± 0.00d 73.89 ± 6.73de 78.33 ± 2.8de 81.33 ± 2.31c 69.45 ± 4.81d 77.50 ± 0.00de 76.67 ± 2.89d 0.36 ± 2.31c
2.5 69.45 ± 4.81cd 69.45 ± 4.81cd 75.00 ± 0.00de 80.00 ± 0.00c 69.45 ± 4.81d 75.00 ± 4.33d 75.00 ± 0.00d 0.36 ± 2.31c
3 66.67 ± 0.00c 69.45 ± 4.91cd 72.22 ± 4.81cd 77.78 ± 3.85c 66.67 ± 0.00cd 70.00 ± 0.00c 66.67 ± 0.00c 0.36 ± 6.16c
3.5 66.67 ± 0.00c 61.11 ± 9.62c 66.67 ± 0.00c 68.89 ± 7.70b 61.11 ± 9.62c 70.00 ± 0.00c 55.56 ± 9.62b 0.36 ± 6.16c
4 55.56 ± 9.62b 50.00 ± 0.00b 55.56 ± 9.62b 64.44 ± 7.70b 50.00 ± 0.00b 55.00 ± 0.00b 50.00 ± 0.00b 0.36 ± 0.00c
F value 126.10*** 80.95*** 139.22*** 134.43*** 91.03*** 390.57*** 161.72***
Values shown are Mean ± S.D. and values in the same column for the same category of time, followed by the same letter do not differ signifi-
cantly at P = 0.05 (Duncan’s test). Each datum represents the mean of three replicate values. ***P < 0.001. A1, A2, and A3 were formulated with
Poloxamer 407 and contain 1, 3 and 5% aspirin respectively, while, B1, B2 and B3 were formulated with Soluplus and contain 1, 3 and 5% aspirin
respectively. P/V: Paw volume in ml.
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include elimination or inhibition of ulcers in patient on long
term therapy, better disease management, ease of formula-
tion and scale, and safety in terms of excipient used in
formulation. There is a need to further study this formula-
tion and all its aspects in order to ensure that aspirin SLMs
get to the market soon so that patients would be able to benefit
from them.
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Table 5 – The ulcer inhibitory properties of aspirin-
loaded SLMs.
SLM batches Ulcer
score
Ulcer
inhibition (%)
Ulcer
diameter (mm)
A1 1.00 75* Lesion <1
A2 2.00 50* Lesion ≤2
A3 3.00 25* Lesion ≤2
B1 1.00 75* Lesion <1
B2 2.00 50* Lesion ≤2
B3 3.00 25* Lesion ≤2
Pure aspirin (G) 4.00 0 Lesion ≥2
Normal saline (H) 0.00 100 No lesion
* Significantly different at P < 0.05 compared to control (batch G);
A1, A2, and A3 were formulated with Poloxamer 407 and contain
1, 3 and 5% aspirin respectively, while, B1, B2 and B3 were formu-
lated with Soluplus and contain 1, 3 and 5% aspirin respectively.
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